Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Paxil (Paroxetine) – US: Mylan granted TRO against GlaxoSmithKline and Apotex prohibiting supply, sale and/or importing of a generic version of Paxil CR (SmartBrief) (GenericsWeb)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Chan denies pharma influence as WHO review proceeds (IP Watch)

The problem with the ‘access to medicine’ debate (Spicy IP)

Africa: Fake drug process in Kenya! And compulsory licensing (Afro-IP)

Europe: Notice from the European Patent Office dated 7 July 2010 concerning inventions which involve the use of or concern biological material (WIPO)

Europe: Notice from the European Patent Office dated 20 September 2010 concerning the non-acceptance of Swiss-type claims for second or further medical use following decision G 2/08 of the Enlarged Board of Appeal (WIPO)

India: Drug marketing approvals may be delinked from patent status (GenericsWeb)

India: The realities of traditional knowledge and patents (IP Watch)

India: No Zandu balm for Dabangg? (Spicy IP) (Spicy IP)

India: The Pegasys compulsory licensing puzzle? (Spicy IP)

India: Delhi High Court denies grant of interim injunction to Bristol Myers Squibb (Spicy IP)

India: Trends in ‘oppositions’ against pharmaceutical patents (Spicy IP)

India: Local pharma in patent rush (Spicy IP)

UK: Circadin appeal now published in the RPC – refusal to grant a supplementary protection certificate for Circadin (SPC blog)

US: An interesting preview of Myriad? (Patently-O)

US: Genentech seeks declaratory judgment of non-infringement of ‘antibody purification’ patents (Patent Docs)

US: Senators vigorously object to the inclusion of patent settlement provisions in FY 2011 Appropriations Bill (FDA Law Blog)

US: A high wire balancing act: FDA and CMS to consider parallel review of medical products (FDA Law Blog)

US: Reform of the de novo classification process needs to be a top priority (FDA Law Blog)

USPTO looking for ways to incentivize humanitarian technologies (Patent Docs)

US: Biosimilar approval pathway: Who will be first? (Patent Docs)

US statement to 48th WIPO general assemblies on IGC on genetic resources, traditional knowledges and folklore (Knowledge Ecology International)

US: California’s Green Chemistry Regulations; a lot of R&R (requirements and responsibilities) for regulated industry (FDA Law Blog)

 

Products

AndroGel (Testosterone) – US: Sham litigation claims against Par and Paddock continue in AndroGel litigation (Patent Docs)

Aplenzin ER (Bupropion) – US: Patent infringement complaint filed following Paragraph IV certification: Biovail Laboratories International SRL v. Par Pharmaceutical Companies, Inc. et al (Patent Docs)

Baraclude (Entecavir) – US: Patent infringement complaint filed following Paragraph IV certification: Bristol-Myers Squibb Co. v. Teva Pharmaceuticals USA Inc. et al. (Patent Docs)

Carbatrol (Carbamazepine) – US: Taro and Shire settle Carbatrol patent dispute (Patent Docs)

Copaxone (Glatiramer acetate) – US: Teva files complaint against Mylan for infringement of four Copaxone related patents (SmartBrief) (IP Factor)

Effexor (Venlafaxine) – US: Apotex and Wyeth settle Effexor patent suit (Patent Docs)

Famvir (Famciclovir) – US: Novartis sues FDA over generic Famvir; alleges that FDA failed to require a split certification (FDA Law Blog) (FDA Law Blog)

Foltx, Folbee, and/or Folbic (Folic acid)– US: Pamlab files patent infringement suit against Allegis over folic acid products represented as substitutable for its own (Patent Docs)

Gemzar (Gemcitabine) – US: Washington Legal Foundation files amicus brief: Sun Pharmaceutical Industries, Ltd. v. Eli Lilly & Co. (Patent Docs)

Herceptin (Trastuzumab) – US: Patent infringement complaint: GlaxoSmithKline LLC v. Roche Holding Ltd. et al. (Patent Docs)

Lovaza (Omega 3 acid) – US: Patent infringement complaint filed following a Paragraph IV certification: Pronova BioPharma Norge AS v. Teva Pharmaceuticals USA Inc. et al. (Patent Docs)

Paxil (Paroxetine) – US: Mylan granted TRO against GlaxoSmithKline and Apotex prohibiting supply, sale and/or importing of a generic version of Paxil CR (SmartBrief)

Zegerid (Omeprazole/Sodium bicarbonate) – US: Patent infringement complaints filed following Paragraph IV certification: Schering-Plough Healthcare Products, Inc. et al. v. Par Pharmaceutical, Inc; Schering-Plough Healthcare Products, Inc. et al. v. Perrigo Co. et al. (Patent Docs)